Tyra Biosciences (TYRA) Expected to Announce Quarterly Earnings on Wednesday

Tyra Biosciences (NASDAQ:TYRA) will likely be releasing its Q2 2025 earnings data before the market opens on Wednesday, August 6th. Analysts expect Tyra Biosciences to post earnings of ($0.53) per share for the quarter.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.02. On average, analysts expect Tyra Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Tyra Biosciences Stock Performance

Shares of TYRA opened at $10.65 on Tuesday. Tyra Biosciences has a 1 year low of $6.42 and a 1 year high of $29.60. The company has a market cap of $565.41 million, a price-to-earnings ratio of -6.53 and a beta of 1.08. The firm has a fifty day moving average of $10.12 and a 200-day moving average of $10.68.

Insider Activity at Tyra Biosciences

In related news, Director Gilla Kaplan sold 30,000 shares of the company’s stock in a transaction on Thursday, June 12th. The stock was sold at an average price of $10.31, for a total value of $309,300.00. Following the completion of the transaction, the director directly owned 59,623 shares in the company, valued at approximately $614,713.13. This represents a 33.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold 61,392 shares of company stock valued at $628,358 in the last three months. Corporate insiders own 15.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new stake in shares of Tyra Biosciences in the first quarter valued at $324,000. Goldman Sachs Group Inc. boosted its holdings in Tyra Biosciences by 21.7% during the first quarter. Goldman Sachs Group Inc. now owns 78,006 shares of the company’s stock worth $725,000 after buying an additional 13,896 shares during the last quarter. Woodline Partners LP bought a new position in Tyra Biosciences during the first quarter worth about $931,000. Finally, Millennium Management LLC boosted its holdings in Tyra Biosciences by 28.2% during the first quarter. Millennium Management LLC now owns 404,165 shares of the company’s stock worth $3,759,000 after buying an additional 89,024 shares during the last quarter. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on TYRA shares. Piper Sandler started coverage on shares of Tyra Biosciences in a report on Wednesday, May 21st. They issued an “overweight” rating and a $33.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Tyra Biosciences in a research note on Tuesday, July 1st. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Tyra Biosciences has a consensus rating of “Buy” and an average price target of $30.83.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.